CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT02168907

Public ClinicalTrials.gov record NCT02168907. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Study identification

NCT ID: NCT02168907
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Wake Forest University Health Sciences; Other
Enrollment: 1 participant

Conditions and interventions

Conditions

Interventions

6,8-bis(benzylthio)octanoic acid Drug
bendamustine hydrochloride Drug
laboratory biomarker analysis Other
rituximab Biological

Drug · Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2014
Primary completion: Jan 31, 2015
Completion: Jan 31, 2015
Last update posted: Jul 1, 2018

2014 – 2015

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Comprehensive Cancer Center of Wake Forest University	Winston-Salem	North Carolina	27157	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02168907, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2018 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02168907 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →